Boston Scientific’s Watchman FLX device, the latest version of its left atrial appendage closure system, was approved by the FDA in 2023. Courtesy of Boston Scientific
The company hopes to launch its next-generation Watchman system in the second half of 2027 or early 2028.
October 1, 2025 – Elise Reuter, Senior Reporter –
Boston Scientific is working on a new version of its Watchman device, company leaders said at a Tuesday investor presentation.
Angelo De Rosa, global president of Boston Scientific’s Watchman business, said the company is working on a version of Watchman that “will provide an answer, stability and unprecedented adaptability to each possible anatomy.”
The company plans to begin enrollment next year for an upcoming U.S. investigational device exemption study, and hopes to launch the device in the second half of 2027 or early 2028.
Watchman is used to reduce the risk of stroke in people with atrial fibrillation by sealing off the left atrial appendage, a small pouch in the heart that can be a source of blood clots. Boston Scientific received Food and Drug Administration approval for its third-generation version of the device, the Watchman FLX Pro, in 2023.
